Physician profile
Demetrious Blackmon
NPI 1578592994
$1,182.44
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.84 · 2020: $106 · 2021: $34.50 · 2022: $33.32 · 2023: $17.37 · 2024: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634 · Travel and Lodging: $288 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.71 |
| Travel and Lodging | $287.58 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $823.32 | 2024 | Ellipsys Vascular Access System |
| Astrazeneca Pharmaceuticals LP | $94.25 | 2020 | |
| Baxter Healthcare | $80.60 | 2024 | Renal - Chronic |
| Glaxosmithkline, LLC. | $40.85 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $39.40 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $21.30 | 2019 | |
| Akebia Therapeutics INC | $20.66 | 2022 | |
| Viiv Healthcare Company | $17.37 | 2023 | |
| Alexion Pharmaceuticals, INC. | $17.06 | 2019 | |
| Daiichi Sankyo INC. | $16.93 | 2019 | |
| Travere Therapeutics, INC. | $10.70 | 2019-2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Demetrious Blackmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.